Nalaganje...
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T cell lymphoma patients
Romidepsin is the second histone deacytelase inhibitor (HDACi) approved for the treatment of advanced stages of cutaneous T cell lymphoma (CTCL). Recent in vitro data suggests that HDACi suppress immune function although these findings have not been confirmed in patients. Thus, we serially examined...
Shranjeno v:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3638752/ https://ncbi.nlm.nih.gov/pubmed/22367792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23112 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|